Reneo Pharmaceuticals, Inc.
RPHM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $2,458,653 | $627,367 | $627,367 |
| - Cash | $70,331 | $83,374 | $96,661 | $110,761 |
| + Debt | $120 | $823 | $955 | $1,085 |
| Enterprise Value | – | $2,376,102 | $531,661 | $517,691 |
| Revenue | $0 | $0 | $0 | -$734 |
| % Growth | – | – | 100% | – |
| Gross Profit | $0 | $0 | $0 | -$662 |
| % Margin | – | – | – | 90.2% |
| EBITDA | $204 | -$16,324 | -$17,000 | $35,937 |
| % Margin | – | – | – | -4,896.1% |
| Net Income | $0 | $0 | $0 | $37,341 |
| % Margin | – | – | – | -5,087.3% |
| EPS Diluted | -1.09 | -1.14 | 0 | 1.08 |
| % Growth | 4.4% | – | -100% | – |
| Operating Cash Flow | -$13,037 | -$13,274 | -$14,005 | -$3,543 |
| Capital Expenditures | -$6 | -$13 | -$18 | -$25 |
| Free Cash Flow | -$13,043 | -$13,287 | -$14,023 | -$3,568 |